ASX-listed health technology firm Jayex is confident it is still a going concern despite a 14 per cent fall in revenue and a flatlining share price.

Releasing its annual report to December 31 yesterday, the company, which earns most of its revenue from its UK arm, admitted that 2017 was a challenging year but its actual losses are less than the preceding period, when it reported a $4m impairment.